Why the study?
Recent pharmacological and instrumental progress in coronary treatment prompts reconsideration of treatment and early screening for silent myocardial ischemia to reduce cardiac morbidity and mortality in patients with diabetes.
Highlights the importance of early screening and treatment for silent myocardial ischemia in diabetic patients to reduce cardiovascular morbidity and mortality.
May support viewing diabetes as vascular disease; leaves open need for targeted trials in expanding populations.
The outlook epidemiological auguring an increase considerable the number of sub-jects with diabetes and cardiological problem during diabetes, and the recent prog-ress registered in the explorations and the treatment of coronary are necessary for to continue research. Since long been recognized as a factor of risk vascular age, the diabetes can be regarded as a genuine vascular disease in because of the frequency and in the severity. The share growing, observed and expected, of the population of diabetics, whose prognosis life is dominated by the complication’s coronary up the diabetes mellitus among the priorities of health public in France. The specifi c features of diabetic coronary artery disease, marked by the often-insidious nature of its development, place silent myocardial ischemia (IMS) and possible atheromatous involvement of the epicardial coronary artery trunks at the center of the diagnostic and therapeutic approach. The progress, drug and instrumentals, the treatment of the inadequacy coronary lead naturally to reconsider the treatment, and therefore the screening early to IMS in the aim of reducing the morbidity and the mortality heart of patients with diabetes.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: